While PTN 151–166 exhibited lower performance for separating AD from controls compared to the core biomarkers in the validation set (Fig. 4f), it should be kept in mind that this difference may to a large degree reflect differences in the performance of the analytical methods used rather than in the performance of the respective biomarkers; the TMT10-plex method used for quantifying PTN 151–166 is designed for global peptide quantification in explorative studies while Aβ42, T-tau, and P-tau were measured using highly optimized ELISA assays that can be expected to have lower variation. This evidence concerns the gene MAPT and Alzheimer disease.